Date Title Description PDF
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download

Pages

Date Title Description PDF
31 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 24 May and 30 May 2024 Download
24 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 17 May and 23 May 2024 Download
21 May 2024 Announcement of general shareholders’ meeting Publication of the announcement of the call to the General Shareholders’ Meeting and the documentation related thereto.   Download
17 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 10 May and 16 May 2024 Download
10 May 2024 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 2 May and 9 May 2024 Download

Pages

Date Title Description PDF
04 Apr 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2019 Download
19 Mar 2019 R&D: new licenses, patents and registered trademarks ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia Download
26 Feb 2019 Informe Anual de Remuneraciones de los Consejeros ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors  Download
26 Feb 2019 Informe Anual de Gobierno Corporativo ROVI releases the 2018 Annual Corporate Governance Report Download
26 Feb 2019 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages